Press Releases
OmegaBrite Wins Award For Creating 1st High Concentrate High EPA Omega-3 and Elevating Standards of Industry For Purity, Scientific Efficacy and Concentration
OmegaBrite, the first high EPA, high concentrate Omega-3 on the market, known for elevating the standards of the entire Omega-3 industry for purity concentration and scientific efficacy, today announced that it has been recognized as the Product of Merit in the 2007 Nutrition Business Journal Business Achievement Awards for creating the category of high EPA supplements.OmegaBrite High EPA Omega-3 Supplement Earns Nutrition Business Journal Business Achievement Award
In recognition of the creation of high concentrate Omega-3 supplements category
Waltham, Mass., April 15 PR Newswire
OMEGA-3 OMEGABRITE SHOWS BENEFIT IN CHILDREN WITH BIPOLAR DISORDER
BOSTON, MA, April 4, 2007 A recently published study by researchers at Harvard�s Massachusetts General Hospital shows that a specially formulated Omega-3 fatty acid supplement showed beneficial results in a study of children with bipolar disorder.
OmegaBrite, the first high EPA, high concentrate Omega-3 on the market, known for elevating the standards of the entire Omega-3 industry for purity concentration and scientific efficacy, today announced that it has been recognized as the Product of Merit in the 2007 Nutrition Business Journal Business Achievement Awards for creating the category of high EPA supplements. These awards acknowledge outstanding leaders in the nutrition marketplace in categories ranging from the latest developments in research and technology to the newest supplements brought to market.
States the Nutrition Business Journal
"OmegaBrite was the first high concentrate, high EPA Omega-3 available to the public and created awareness of the importance of Omega-3 and the importance of EPA as the body's natural anti-inflammatory molecule.
OmegaBrite not only created the category of high EPA concentrate Omega-3 but also elevated the standards of the entire industry for purity, concentration and scientific efficacy."
OmegaBrite will receive the award at the annual Nutrition Business Journal Awards Summit in July 2008 in Dana Points, CA.
"We are pleased that OmegaBrite has been recognized by Nutrition Business Journal as the Product of Merit," said Dr. Carol A. Locke, President of OmegaBrite.
"At OmegaBrite, we are proud to be at the forefront of this industry in bringing attention to the positive benefits of high EPA Omega-3 fish oils. It is profoundly gratifying to know that with OmegaBrite we are providing a safe, natural way for consumers to obtain the benefits of essential Omega-3s."
OmegaBrite was created in 1999 by Carol A. Locke, M.D., who foresaw that high EPA, Omega-3 fatty acids in highly concentrated form would prove a safe and effective treatment of mood disorders, cardiac health, ADD/ADHD, cognitive development and joint pain, as well as a preventative measure for all people.
May 25, 2008 Reuters New Release April 15, 2007
OMEGA-3 SHOWS BENEFIT IN CHILDREN WITH BIPOLAR DISORDER
The OmegaBrite supplement of high EPA Omega-3 fatty acids was tested for effectiveness and safety on 20 boys and girls with bipolar disorder, 6 to 17 years old, over an eight-week period. Thirty five percent of the children experienced a greater than 50% percent reduction in symptoms with no adverse side effects.
Biederman and Wozniak's previous study using Olanzepine and Risperidal showed similar results to the Omega-3 supplement with a 53% reduction in mania for olanzepine and a 69% reduction in mania using risperidal.
The pharmaceutical drugs in that prior study had side effects of sedation, weight gain, increased prolactin levels and increased heart rate. The Omega-3 OmegaBrite had no side effects and was well tolerated. The children receiving 6 capsules per day of the omega-3 omegabrite had benefit.
Results from this prospective, open study of monotherapy with Omega-3 fatty acids in the over-the-counter product OmegaBrite suggest that manic symptoms can be rapidly reduced in youths with BPD with a safe and well-tolerated nutritional supplement.
The study findings indicate importance of further research on Omega-3, mood disorders and children. The Massachusetts General study, funded by a Stanley Foundation grant, was reported in European Neuropsychopharmacology in February 2007.
April 4, 2007
